Home > News > featured news > Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Future of Healthcare

Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Anumana, Inc. | July 14, 2022 | Read time : 2 min

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use.

The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death.

“Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms. Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.”

Murali Aravamudan, CEO of Anumana

“Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.”

“Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.”

The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request.

About Anumana
Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Spotlight

Revolutionize Your Healthcare Marketing: MORE Patients, FASTER Growth

Transform your medical practice or your healthcare business with customized digital solutions from BraveLabs. Generate patient demand, boost engagement, deliver great patient experiences, improve retention rates, and boost your revenues. Trust our results.

More featured news

Spotlight

Revolutionize Your Healthcare Marketing: MORE Patients, FASTER Growth

Related News

Health Technology

Biosense Webster Launches the OPTRELL™ Mapping Catheter with TRUEref™ Technology for Mapping of Complex Cardiac Arrhythmias

PRNewswire | July 25, 2023

Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced the U.S. launch of the OPTRELL™ Mapping Catheter with TRUEref™ Technology powered by the CARTO® 3 System. The OPTRELL™ Mapping Catheter is a high-density diagnostic catheter, with small electrodes arranged in a fixed array formation to provide high-definition electrophysiological mapping of complex cardiac arrhythmia cases like persistent atrial fibrillation (AFib), redo AFib ablation, atrial tachycardia, and ventricular tachycardia. Cardiac arrhythmias are a growing epidemic. AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide, with up to 6 million of these individuals living in the U.S.1,2 AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.3,4 Catheter ablation is a safe and effective procedure to restore the heart's incorrect electrical signals, which causes an abnormal heart rhythm.5 This new catheter includes 48 electrodes symmetrically distributed across and along six splines and combines with the CARTO® 3 System to deliver intelligent insights and high-resolution directional mapping.6 Additionally, the OPTRELL™ Mapping Catheter has tight electrode spacing and small electrodes, which produce higher signal resolution, resulting in enhanced maps of the heart.7,8 With these high-definition maps, clinicians have a better understanding of where the arrhythmia is occurring and can develop a more effective ablation strategy. "The OPTRELL™ Mapping Catheter has a fixed electrode array structure that provides greater diagnostic insight, which allows physicians to quickly and effectively identify ablation targets," said Pasquale Santangeli, M.D., Ph.D., Cardiovascular Medicine, Cleveland Clinic Main Campus.ii "This catheter and the Local Conduction Vectors give me the confidence to quickly and effectively detect ablation lesion gaps and the arrhythmia substrate, even in the most complex cases, including persistent AFib, redo AFib ablation, atrial tachycardia, and ventricular tachycardia." The OPTRELL™ Mapping Catheter is powered by the CARTO® 3 System, which offers Local Conduction Vectors that display the real-time direction and speed of the electrical impulses traveling through the heart.9 With these Local Conduction Vectors, clinicians gain enhanced understanding of complex circuits and mechanisms and can confidently detect gaps in ablation lesions.7 Together, these technologies can help clinicians quickly identify areas that need ablation and apply more effective therapy in a shorter time. "The OPTRELL™ Mapping Catheter rounds out the Biosense Webster diagnostic mapping portfolio, providing physicians with a comprehensive set of tools, integrated with our CARTO® 3 mapping system, to diagnose and treat arrhythmias," said Jasmina Brooks, President, Biosense Webster, Inc. "This is the latest example of the continued commitment of Biosense Webster to providing clinicians with innovative tools to improve efficiency and effectiveness of procedures and quality of care for patients." The OPTRELL™ Mapping Catheter with TRUEref™ Technology received U.S. Food and Drug Administration (FDA) 510(k) clearance in 2022 and is now available in the U.S. The OPTRELL™ Mapping Catheter with TRUEref™ Technology will be commercially available in Japan later this year. About Biosense Webster Biosense Webster, Inc. is the global market leader in the science and technology behind the diagnosis and treatment of cardiac arrhythmias. Part of Johnson & Johnson MedTech, the specialized medical-technology company is headquartered in Irvine, California, and works across the world to advance the tools and solutions that help electrophysiologists identify, treat, and deliver care. About Johnson & Johnson MedTechi At Johnson & Johnson MedTech,i we unleash diverse healthcare expertise, purposeful technology, and a passion for people to transform the future of medical intervention and empower everyone to live their best life possible. For more than a century, we have driven breakthrough scientific innovation to address unmet needs and reimagine health. In surgery, orthopaedics, vision, and interventional solutions, we continue to help save lives and create a future where healthcare solutions are smarter, less invasive, and more personalized.

Health Technology, AI

Weave Launches AI-Driven Email Marketing Tool for Healthcare Providers

Businesswire | August 02, 2023

Weave a leading all-in-one customer experience platform for small and medium-sized healthcare businesses, today announced the launch of Email Assistant, its second AI-driven engagement product. Now available to its 27,000+ customers, Weave's AI-driven Email Assistant provides an innovative way for healthcare providers to communicate and connect with their patients and clients. By simply inputting the themes that need to be covered in the email, Weave Email Assistant will generate the email text in a matter of seconds, which can then be edited before sending. This tool allows healthcare providers to quickly create, personalize, and automate email marketing campaigns, resulting in improved patient engagement and retention, a higher patient growth rate, and increased awareness of services offered by a practice. “With digital marketing becoming an essential part of running a healthcare business, it’s important to provide simple and effective AI-driven solutions to our customers,” said Branden Neish, Chief Product & Technology Officer at Weave. “With Email Assistant, we reduce both the time requirement and anxiety often associated with creating an email marketing campaign. By harnessing the power of AI, we aim to empower healthcare providers to deliver exceptional patient experiences that drive patient loyalty and business growth.” Email marketing is an essential and often overlooked marketing avenue. According to one study, email marketing generates, on average, $36 of new business for every $1 spent, and 59% of consumers say that email marketing campaigns influence their purchasing decisions. About Weave Weave is a leading all-in-one customer experience platform for small- and medium-sized healthcare businesses. From the first phone call to the final invoice and every touchpoint in between, Weave connects the entire customer journey. Weave’s software solutions transform how local businesses attract, communicate with and engage customers to grow their business. Weave has set the bar for Utah startup achievement & work culture. In the past year, Weave has been named a G2 leader in Patient Engagement, Optometry, Dental Practice Management and Patient Relationship Management software.

Healthcare Analytics

Maxim Healthcare Services Names National Caregiver of the Year

businesswire | September 29, 2023

Barbara Buttchen has been named National Caregiver of the Year by Maxim Healthcare Services (Maxim), a national provider of home healthcare, personal and behavioral care. Buttchen, a nurse in Maxim’s Madison, Wisconsin office was presented with the John “Doc” Langley National Caregiver of the Year award alongside colleagues and fellow nominees during a ceremony in Baltimore, Maryland on September 19. “Barbara makes such a difference in the lives of her patients and their families every day,” said Maxim’s Chief Executive Officer, Jarrod DePriest. We deeply admire Barbara’s dedication to providing quality compassionate in-home care and we are thrilled to present her with this much-deserved recognition. [Source – Business Wire] Selected by a panel of judges for her impactful contributions to the home healthcare community, Buttchen has worked as a nurse for more than 50 years. Described by her colleagues as one of the most selfless, caring, kind, and hard-working individuals, Buttchen prioritizes others’ well-being more than her own. She currently lives with lymphoma but keeps a positive attitude and is always looking for ways to serve others. She extends caregiving to her personal life with activities such as delivering Meals on Wheels to individuals in need, providing care to a friend that has Alzheimer's, and also lending her expertise to a friend’s husband that is wheelchair bound while they travel, so that the vacation can be safe and enjoyable. During the ceremony Barbara shared, “I wanted to be like Florence Nightingale. That’s how I want to be known and live my life. Before I lay my head down on the pillow, I want to make rounds one more time, with the lantern, to see if there’s someone that needs my care. Thank you so much for this honor.” Maxim’s Caregiver of the Year Award Program, which is celebrated annually, recognizes the nurses, home healthcare aides and behavioral direct care workers who all play a vital role in providing compassionate, holistic care for patients who are both medically fragile and who require behavioral and community support. Learn more about Buttchen’s story, here. In addition to honoring Buttchen, Maxim also celebrates another significant milestone this year – providing 35 years of compassionate, holistic home healthcare for patients. DePriest, who has been with Maxim since 1998 and first started with the company as a healthcare recruiter, lauds the Maxim team for this accomplishment. “The healthcare industry has continued to rapidly grow and evolve, and likewise so has Maxim,” said DePriest. “As a mission-driven company, we are passionate about our work and improving the lives of our patients, their families and the communities we serve nationwide. I want to thank our exceptional team for their commitment and service, and to our patients and their families that have welcomed us into their homes.”